212 related articles for article (PubMed ID: 37550187)
21. Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).
Asaad NY; Abd El-Wahed MM; Dawoud MM
J Egypt Natl Canc Inst; 2005 Dec; 17(4):279-90. PubMed ID: 17102815
[TBL] [Abstract][Full Text] [Related]
22. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
24. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
26. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
27. Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Wąsik-Szczepanek E; Szymczyk A; Szczepanek D; Wszoła-Kleinrok J; Chocholska S; Pluta A; Hus M
Adv Clin Exp Med; 2018 Dec; 27(12):1683-1689. PubMed ID: 30156387
[TBL] [Abstract][Full Text] [Related]
28. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Hallek M; Al-Sawaf O
Am J Hematol; 2021 Dec; 96(12):1679-1705. PubMed ID: 34625994
[TBL] [Abstract][Full Text] [Related]
29. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Chanan-Khan AA; Coutre SE; Davis RS; Eradat H; Fletcher CD; Gaballa S; Ghobadi A; Hamid MS; Hernandez-Ilizaliturri F; Hill B; Kaesberg P; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Ma S; Mato A; Mosse C; Schuster S; Siddiqi T; Stephens DM; Ujjani C; Wagner-Johnston N; Woyach JA; Ye JC; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2022 Jun; 20(6):622-634. PubMed ID: 35714675
[TBL] [Abstract][Full Text] [Related]
30. [Clinical Features and Outcomes of the Patients with B-Cell Chronic Lymphoproliferative Disease in the New Drug Era].
Xu CB; Hu M; Shen JZ; Xu HQ; Zheng RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):722-729. PubMed ID: 37356932
[TBL] [Abstract][Full Text] [Related]
31. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Siddiqi T; Maloney DG; Kenderian SS; Brander DM; Dorritie K; Soumerai J; Riedell PA; Shah NN; Nath R; Fakhri B; Stephens DM; Ma S; Feldman T; Solomon SR; Schuster SJ; Perna SK; Tuazon SA; Ou SS; Papp E; Peiser L; Chen Y; Wierda WG
Lancet; 2023 Aug; 402(10402):641-654. PubMed ID: 37295445
[TBL] [Abstract][Full Text] [Related]
32. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
33. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.
Hoeller S; Zhou Y; Kanagal-Shamanna R; Xu-Monette ZY; Hoehn D; Bihl M; Swerdlow SH; Rosenwald A; Ott G; Said J; Dunphy CH; Bueso-Ramos CE; Lin P; Wang M; Miranda RN; Tzankov A; Medeiros LJ; Young KH
Hum Pathol; 2013 Jan; 44(1):110-21. PubMed ID: 22944294
[TBL] [Abstract][Full Text] [Related]
34. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
35. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
36. Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse.
Randhawa B; Lewis E; Owen C
Semin Oncol Nurs; 2021 Aug; 37(4):151177. PubMed ID: 34281733
[TBL] [Abstract][Full Text] [Related]
37. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.
O'Brien SM; Brown JR; Byrd JC; Furman RR; Ghia P; Sharman JP; Wierda WG
Front Oncol; 2021; 11():720704. PubMed ID: 34858810
[TBL] [Abstract][Full Text] [Related]
38. The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.
Moia R; Patriarca A; Schipani M; Gaidano G
Cancer J; 2021 Jul-Aug 01; 27(4):266-274. PubMed ID: 34398553
[TBL] [Abstract][Full Text] [Related]
39. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
[TBL] [Abstract][Full Text] [Related]
40. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]